ABOUT NEWAMSTERDAM PHARMA
NewAmsterdam Pharma Holding B.V. (“NewAmsterdam Pharma”) is a private clinical-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where traditional therapies have not been sufficiently successful or well-tolerated. NewAmsterdam Pharma is investigating obicetrapib, a next-generation oral, low-dose and once-daily cholesteryl ester transfer protein (“CETP”) inhibitor, as the preferred low-density lipoprotein (“LDL”) cholesterol-lowering therapy for high-risk cardiovascular disease (“CVD”) patients.
Results from NewAmsterdam Pharma’s ROSE Phase 2b trial (presented at AHA Scientific Sessions in 2021 and recently published in Nature Medicine here) included observations that patients receiving obicetrapib 10 mg experienced a median reduction in LDL-C by 51% versus baseline in patients on statin therapy (vs. a 7% reduction in the placebo arm). NewAmsterdam Pharma is currently evaluating obicetrapib in three Phase 3 trials, BROADWAY, BROOKLYN and PREVAIL, and a secondary Phase 2 trial, ROSE2. These studies are intended to examine obicetrapib as a combination therapy as well as its efficacy in adjunct to diet and a maximally tolerated lipid-lowering therapy, and reduction of major adverse cardiovascular events.
See the following relevant publications for additional learnings from the discovery and development of prior CETP inhibitors and associated preclinical and clinical observations:
In the Journal of Medicinal Chemistry, Vachal et. al. discuss preclinical and clinical evidence for a CETP inhibitor to reduce coronary heart disease risk by means of high-density lipoprotein (“HDL”) increase and LDL reduction. Read more here.
In the European Heart Journal, Hopewell et. al. discuss the long-term safety and efficacy results of a CETP inhibitor, together with intensive statin therapy, in reducing the risk of major coronary events in patients with atherosclerotic vascular disease. Read more here.